← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Danaher DHR $158B	995	+29	+3%	$46B
2	2 Thermo Fisher Scientific TMO $249B	971	-4	-0.4%	$43.8B
3	3 Novartis NVS $279B	926	-19	-2%	$21.6B
4	4 Illumina ILMN $41B	564	-5	-0.9%	$24.6B
5	5 Regeneron Pharmaceuticals REGN $80.1B	563	+22	+4%	$34.1B
6	6 Agilent Technologies A $49.1B	529	-32	-6%	$9.73B
7	7 Ionis Pharmaceuticals IONS $7.1B	314	-39	-11%	$4.28B
8	8 Revvity RVTY $17B	310	+4	+1%	$4.74B
9	9 Alnylam Pharmaceuticals ALNY $30B	258	-20	-7%	$5.26B
10	10 Charles River Laboratories CRL $14.4B	258	-3	-1%	$2.93B
11	11 Myriad Genetics MYGN $397M	235	0	0%	$3.42B
12	12 DELISTED bluebird bio BLUE	192	-43	-18%	$3.13B
13	13 Bruker BRKR $8.47B	177	+18	+11%	$1.91B
14	14 DELISTED CATALENT, INC. CTLT	176	+27	+18%	$3.04B
15	15 Precigen PGEN $2.63B	173	0	0%	$3.23B
16	16 Ultragenyx Pharmaceutical RARE $1.47B	162	+11	+7%	$3.41B
17	17 PTC Therapeutics PTCT $4.98B	157	+2	+1%	$884M
18	18 Sarepta Therapeutics SRPT $1.78B	149	+19	+15%	$892M
19	ISEE 19 DELISTED IVERIC bio, Inc. Common Stock ISEE	144	+5	+4%	$1.29B
20	20 DELISTED SANGAMO THERAPEUTICS INC SGMO	141	-15	-10%	$297M
21	21 Azenta AZTA $1.63B	137	+9	+7%	$747M
22	22 Standard BioTools LAB $248M	109	+2	+2%	$252M
23	23 Arrowhead Research ARWR $8.25B	103	+9	+10%	$148M
24	24 DELISTED Adverum Biotechnologies ADVM	92	-4	-4%	$144M
25	25 Atara Biotherapeutics ATRA $96M	91	+17	+23%	$614M